Skip to main content

Context Therapeutics, Inc. (CNTX)

NASDAQ: CNTX · Delayed Price · USD
5.25
+0.15 (2.94%)
After-hours:Oct 20, 2021 7:33 PM EDT
5.10
0.10 (2.00%)
At close: Oct 20, 4:00 PM

Company Description

Context Therapeutics® is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer.

Our development team is advancing a pipeline of innovative therapies with a primary focus on treating female cancers, which include, but are not limited to, breast, ovarian and endometrial cancer.

Our first program and lead product candidate, onapristone extended release (“ONA-XR”), builds upon a foundation of successful drug development by our management team and advisors in the field of female hormone-dependent cancers.

We believe that ONA-XR, in combination with current standard-of-care anti-estrogens, has the potential to significantly improve clinical outcomes. ONA-XR is currently being evaluated in three Phase 2 trials, one Phase 1b/2 trial and two Phase 0 biomarker pharmacodynamic trials in women with primary or metastatic breast, ovarian and endometrial cancers.

These trials are intended to establish safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity at the recommended Phase 2 dose of ONA-XR to guide potential advancement in Phase 3 development in 2023.

Context Therapeutics, Inc.
CountryUnited States
Founded2015
IPO DateOct 20, 2021
IndustryPharmaceuticals
SectorHealth Care
Employees2
CEOMartin Lehr

Contact Details

Address:
3675 Market Street, Suite 200
Philadelphia, PA 19104
United States
Phone267-225-7416
Websitecontexttherapeutics.com

Stock Details

Ticker SymbolCNTX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$5.00
CIK Code1842952
Employer ID32-0402377

Key Executives

NamePosition
Martin LehrCo-Founder, Chief Executive Officer and Director
Dr. Tarek SahmoudChief Medical Officer
Dr. Bill Rencher Ph.D.Head of CMC and Regulatory
Dr. Felix Kim Ph.D.Co-founder and Chair of Scientific Advisory Board
Eileen Kittrick CPAController
Alex Levit Esq.Chief Legal Officer and Corporate Secretary
Dr. Evan G. DickSenior Vice President of Research & Development